Sacituzumab tirumotecan anlotinib extensive-stage small cell lung cancer trial registration

A new clinical trial record was added to the ClinicalTrials.gov registry (NCT07501169) for a Phase 1/2 study evaluating sacituzumab tirumotecan (a Trop-2 directed antibody-drug conjugate) combined with anlotinib (a tyrosine kinase inhibitor) in patients with extensive-stage small cell lung cancer. The trial registration includes standard elements such as eligibility criteria, study design, endpoints, and investigator information.

Trial sponsors subject to FDAAA 801 requirements should ensure their applicable trials are properly registered. Healthcare providers and patients can access detailed enrollment criteria and study locations through the ClinicalTrials.gov record. This registry entry does not impose new compliance obligations but supports transparency requirements for clinical research.